| scholarly article | Q13442814 |
| P50 | author | Philip Scheltens | Q22280357 |
| Marissa D Zwan | Q91736067 | ||
| Mike P. Wattjes | Q96171523 | ||
| Lorena Rami | Q114399479 | ||
| José Luis Molinuevo | Q38548964 | ||
| Frederik Barkhof | Q42355589 | ||
| Niels D Prins | Q48357915 | ||
| Charlotte Teunissen | Q56887227 | ||
| Wiesje van der Flier | Q57525101 | ||
| Ingrid S van Maurik | Q57566323 | ||
| Olive Melissa Minor Peters | Q57888941 | ||
| Sander C J Verfaillie | Q86297993 | ||
| Femke Bouwman | Q88621754 | ||
| Frank Jessen | Q90045707 | ||
| Rosalinde E R Slot | Q90782257 | ||
| Steffen Wolfsgruber | Q91095858 | ||
| P2093 | author name string | Johannes Berkhof | |
| P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia | Q24598142 | ||
| The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease | Q28005463 | ||
| Mild cognitive impairment: clinical characterization and outcome | Q28140626 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
| Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | Q29620245 | ||
| Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline | Q30239789 | ||
| Alzheimer's disease | Q30251865 | ||
| Communicating mild cognitive impairment diagnoses with and without amyloid imaging | Q33640373 | ||
| A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. | Q33731693 | ||
| Estimating and disclosing the risk of developing Alzheimer‘s disease: challenges, controversies and future directions | Q34135724 | ||
| Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study | Q34274231 | ||
| Primary age-related tauopathy (PART): a common pathology associated with human aging | Q34445021 | ||
| Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers | Q34682521 | ||
| Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults | Q34922621 | ||
| A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease | Q35049917 | ||
| Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues | Q35838385 | ||
| A Bayesian model of shape and appearance for subcortical brain segmentation | Q36158330 | ||
| An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease | Q36650399 | ||
| ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials | Q37235850 | ||
| Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer's disease | Q38252671 | ||
| Biochemical and neuroimaging studies in subjective cognitive decline: progress and perspectives. | Q38416584 | ||
| Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment | Q38773523 | ||
| Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects | Q40285515 | ||
| Implementation of subjective cognitive decline criteria in research studies | Q40483941 | ||
| T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study | Q41325619 | ||
| Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project | Q42655681 | ||
| Diagnostic impact of CSF biomarkers in a local hospital memory clinic | Q43044802 | ||
| Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints | Q44280870 | ||
| Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment | Q47232869 | ||
| Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project | Q47429580 | ||
| Early-stage and preclinical Alzheimer disease | Q48342215 | ||
| Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop | Q48342894 | ||
| Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis | Q48579172 | ||
| Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the Development of Screening guidelines and diagnostic Criteria for Predementia Alzheimer's disease study | Q48779629 | ||
| Optimizing patient care and research: the Amsterdam Dementia Cohort. | Q50712172 | ||
| Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. | Q51867713 | ||
| NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Q52589491 | ||
| Amsterdam Dementia Cohort: Performing Research to Optimize Care. | Q52644592 | ||
| Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. | Q52886859 | ||
| Volume reduction of the entorhinal cortex in subjective memory impairment. | Q53273914 | ||
| Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment | Q57814354 | ||
| Machine Learning for Predicting Cognitive Diseases: Methods, Data Sources and Risk Factors | Q58111439 | ||
| Sex differences in Alzheimer disease — the gateway to precision medicine | Q60637417 | ||
| Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts | Q71670103 | ||
| Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia | Q90568308 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cerebrospinal fluid | Q54196 |
| P304 | page(s) | 33 | |
| P577 | publication date | 2019-04-16 | |
| P1433 | published in | Alzheimers Research & Therapy | Q15716761 |
| P1476 | title | Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project | |
| P478 | volume | 11 |
Search more.